Baseline Therapeutics

Baseline Therapeutics is a clinical-stage biotechnology company developing addiction therapeutics centered on glucagon-like peptide 1 receptor agonist medicines for substance use disorders. The company launched publicly in January 2026 and is advancing BT-001, a once-weekly GLP-1 receptor agonist candidate, toward Phase 3 development in alcohol use disorder. Baseline is also extending the same program into stimulant use disorders, including cocaine and methamphetamine use disorders, and is evaluating opioid use disorder and other compulsive or behavioral indications. The company positions its strategy around leveraging an established metabolic drug class with existing safety experience to develop potentially differentiated treatments for addiction.